The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 04, 2017
Filed:
Sep. 11, 2014
Institute of Cancer Research: Royal Cancer Hospital (The), London, GB;
Alan Ashworth, London, GB;
Christopher James Lord, London, GB;
Richard James Rowland Elliott, London, GB;
Dan Niculescu-Duvaz, Sutton Surrey, GB;
Roderick Alan Porter, London, GB;
Rehan Aqil, Cambridge, GB;
Raymond John Boffey, Cambridge, GB;
Melanie Jayne Bayford, Cambridge, GB;
Stuart Firth-Clark, Cambridge, GB;
Anna Hopkins, Cambridge, GB;
Ashley Nicholas Jarvis, Cambridge, GB;
Trevor Robert Perrior, Cambridge, GB;
Philip Alan Skone, Cambridge, GB;
Rebekah Elisabeth Key, St Helier, GB;
Abstract
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.